Research programme: haemophilia therapeutics - Amunix/Biogen

Drug Profile

Research programme: haemophilia therapeutics - Amunix/Biogen

Alternative Names: Blood coagulation factors recombinant - Amunix/Biogen; Factor IX recombinant - Amunix/Biogen; Factor VIIa recombinant - Amunix/Biogen Idec; Factor VIII recombinant - Amunix/Biogen Idec; FIXFc-XTEN; rFIXFc-XTEN; rFVIIIFc-VWF-XTEN; rFVIIIFc-XTEN-vWF; XTENylated Factor VIII

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Amunix; Biogen Idec
  • Developer Amunix; Biogen
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A; Haemophilia B

Most Recent Events

  • 05 Jan 2017 A recombinant Factor IX product candidate licensed to Biogen
  • 03 Dec 2016 Preclinical development of Haemophilia therapeutics for Haemophilia A and Haemophilia B is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top